Lawrence Blatt - Jul 7, 2022 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Chief Executive Officer
Signature
/s/ Lucinda Y. Quan, as attorney-in fact for Lawrence M. Blatt
Stock symbol
ALGS
Transactions as of
Jul 7, 2022
Transactions value $
$0
Form type
4
Date filed
7/11/2022, 04:13 PM
Previous filing
Feb 8, 2022
Next filing
Mar 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +162K $0.00 162K Jul 7, 2022 Common Stock 162K $1.41 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.